Protagenic Therapeutics, Inc.
corporate_fare Company Profile
Protagenic Therapeutics, Inc. (OTC:PTIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for PTIX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for PTIX spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- Protagenic Closes $1.5M Initial Tranche of Up to $5M Private Placement at $0.61/Share
- Micro-Cap Biotech Raises $1.5M Upfront, Up to $5M, to Fund First U.S. Anxiety Trial
- Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in GAD
- Cash Runway Narrows to Q3 2026 as Going Concern Doubts Deepen for Protagenic Therapeutics
- Protagenic Therapeutics 10-K: Going Concern, Nasdaq Delisting, and $7.3M Unwind Gain
Financial Snapshot
Short Interest & Short Volume
6.57 days to coverFINRA reported short interest of 12,907 shares in PTIX as of the October 30, 2026 settlement, a 0.3% decrease from the prior period — about 6.6 days to cover at its recent average daily volume. On November 20, 2026, 0.9% of PTIX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.